{
    "Trade/Device Name(s)": [
        "FRENDTM PSA Plus",
        "FRENDTM system"
    ],
    "Submitter Information": "NanoEnTek, Inc.",
    "510(k) Number": "K124056",
    "Predicate Device Reference 510(k) Number(s)": [
        "P910065/S004"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTJ",
        "KHO"
    ],
    "Summary Letter Date": "May 18, 2013",
    "Summary Letter Received Date": "May 24, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6010",
        "21 CFR 862.2560"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunologic test system",
        "Fluorometer"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Total Prostate Specific Antigen (PSA)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Heparinized plasma",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [
        "Test Cartridge",
        "Transfer pipet"
    ],
    "Instrument(s)/Platform(s)": [
        "FRENDTM system"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Fluorescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Cartridge",
        "Instrument"
    ],
    "Document Summary": "FDA 510(k) summary for FRENDTM PSA Plus fluorescence immunoassay for quantitative measurement of PSA using the FRENDTM system in serum and plasma.",
    "Indications for Use Summary": "Quantitative in vitro diagnostic measurement of total PSA in human serum, heparinized plasma, and EDTA plasma to aid clinicians in the management of patients with prostate cancer.",
    "fda_folder": "Immunology"
}